Bringing expensive Biologics within reach: Oncosimis® Biotech is a research and clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing therapeutic relevant proteins including mAbs, recombinant proteins. Oncosimis® Biotech leverages AcceTT® platform to produce high-quality mAb and recombinant proteins from CHO cells and BacSce® platform to produce endotoxin-free recombinant protein and Fab from E .coli in an efficient and cost-effective manner.
Oncosimis® play an impeccable role in the development of biologic drugs at affordable cost. Oncosimis proprietary technologies have tremendous potential to reduce the production costs of biologic drugs while increasing yield significantly.
Oncosimis® Biotech dedicated to develop and produce bio-therapeutic proteins using two proprietary technology platforms, AcceTT® and BacSec® which provides a distinctive advantage to manufacture biosimilar at affordable costs.
Oncosimis® has leveraged a team of world famous experienced research scientists, doctors, and entrepreneurs in the field of drug discovery, towards manufacturing and commercializing bio-therapeutics.